Shattuck Labs Inc (STTK)

$5.99 -0.14 (-2.28%)
Market Cap 428.67M
Revenue (ttm) 1.00M
Net Income (ttm) -48.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,881.00%
Debt to Equity Ratio 0.00
Volume 354,400
Avg Vol 691,706
Day's Range N/A - N/A
Shares Out 71.56M
Stochastic %K 89%
Beta 1.55
Analysts Strong Sell
Price Target $9.50

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 900 4690
Address:
500 West 5th Street, Suite 1200, Austin, United States
TheLaughingStock1
TheLaughingStock1 Mar. 9 at 11:19 AM
$STTK I only put in a little on this a while back, but now wishing I went big on it! It keeps outperforming and everytime I anticipate the dip, it climbs further! Now I'm afraid to average up!
1 · Reply
S2K_TP
S2K_TP Mar. 7 at 5:46 AM
$STTK king of momentum play. Pt: 10+
0 · Reply
StockScanners
StockScanners Mar. 7 at 5:32 AM
$STTK keep watch if this holds above 5.70
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 6 at 3:08 PM
$STTK I said 'Nest' because that's how we say Next in my country.. Don't laugh at me 👊👊
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 7:08 PM
$STTK Sorry I meant $5.00 not $6.00 hit either way.. Here we are.... With more money 💰 💰
0 · Reply
focafoca99
focafoca99 Mar. 5 at 4:31 PM
$STTK filed an 8-K dated March 5, creating a fresh disclosure point for biotech traders scanning event risk.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 3:30 PM
$STTK Q4 '25 Earnings Results & Recap Shattuck Labs Inc expects to complete enrollment in its Phase 1 clinical trial for SL-325 in Q2 2026 and initiate a Phase 2 clinical trial in CD patients in Q3 2026, with current capital sufficient through 2029.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 2:41 PM
$STTK Moving up towards $6.00 and we have another overnight swing winner.. Keep it going 39 straight 🚨🚨
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 2:35 PM
$STTK Earnings looked good... $4.73 Nest to break 🚨🚨
2 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 25 at 3:05 PM
$STTK in
0 · Reply
Latest News on STTK
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Mar 5, 2026, 6:15 AM EST - 10 days ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Feb 25, 2026, 8:00 AM EST - 18 days ago

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 6, 2026, 8:30 AM EST - 5 weeks ago

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 15, 2025, 4:15 PM EST - 3 months ago

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

Dec 1, 2025, 4:33 PM EST - 3 months ago

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

Shattuck Labs to Participate in Upcoming December Investor Conferences

Nov 20, 2025, 8:00 AM EST - 4 months ago

Shattuck Labs to Participate in Upcoming December Investor Conferences

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 4:30 PM EST - 4 months ago

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript

Oct 10, 2025, 9:16 PM EDT - 5 months ago

Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Oct 2, 2025, 7:51 AM EDT - 5 months ago

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Aug 26, 2025, 6:30 AM EDT - 7 months ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Aug 21, 2025, 10:17 AM EDT - 7 months ago

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 6:30 AM EDT - 7 months ago

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Aug 5, 2025, 6:30 AM EDT - 7 months ago

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 2, 2025, 7:00 AM EDT - 9 months ago

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 4:20 PM EDT - 11 months ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 20, 2025, 9:00 AM EST - 1 year ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Feb 4, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:59 PM EST - 1 year ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Jan 2, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

Oct 23, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

Oct 22, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

Oct 21, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

Oct 20, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Oct 16, 2024, 10:00 AM EDT - 1 year ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

Oct 15, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

Oct 14, 2024, 6:00 PM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 12:23 PM EDT - 1 year ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Oct 1, 2024, 6:30 AM EDT - 1 year ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 30, 2024, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My

Jun 6, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E

May 14, 2024, 4:15 PM EDT - 1 year ago

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024, 7:05 AM EDT - 2 years ago

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

TheLaughingStock1
TheLaughingStock1 Mar. 9 at 11:19 AM
$STTK I only put in a little on this a while back, but now wishing I went big on it! It keeps outperforming and everytime I anticipate the dip, it climbs further! Now I'm afraid to average up!
1 · Reply
S2K_TP
S2K_TP Mar. 7 at 5:46 AM
$STTK king of momentum play. Pt: 10+
0 · Reply
StockScanners
StockScanners Mar. 7 at 5:32 AM
$STTK keep watch if this holds above 5.70
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 6 at 3:08 PM
$STTK I said 'Nest' because that's how we say Next in my country.. Don't laugh at me 👊👊
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 7:08 PM
$STTK Sorry I meant $5.00 not $6.00 hit either way.. Here we are.... With more money 💰 💰
0 · Reply
focafoca99
focafoca99 Mar. 5 at 4:31 PM
$STTK filed an 8-K dated March 5, creating a fresh disclosure point for biotech traders scanning event risk.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 3:30 PM
$STTK Q4 '25 Earnings Results & Recap Shattuck Labs Inc expects to complete enrollment in its Phase 1 clinical trial for SL-325 in Q2 2026 and initiate a Phase 2 clinical trial in CD patients in Q3 2026, with current capital sufficient through 2029.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 2:41 PM
$STTK Moving up towards $6.00 and we have another overnight swing winner.. Keep it going 39 straight 🚨🚨
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 5 at 2:35 PM
$STTK Earnings looked good... $4.73 Nest to break 🚨🚨
2 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 25 at 3:05 PM
$STTK in
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 4:18 PM
$BCAB $STTK $LRE $PVLA •’”
0 · Reply
PhantomStrike
PhantomStrike Feb. 18 at 7:11 AM
$STTK Shattuck Labs is a biotech facing clinical setbacks with pipeline reset requiring significant positive data [citation:historical].
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 8:58 PM
$STTK Current Stock Price: $3.86 Contracts to trade: $5.0 STTK Feb 20 2026 Call Entry: $0.14 Exit: $0.26 ROI: 91% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Gtrading1234
Gtrading1234 Feb. 15 at 6:52 AM
$STTK
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 6:39 PM
$STTK RSI: 43.11, MACD: 0.0269 Vol: 0.27, MA20: 4.08, MA50: 3.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Jan. 28 at 4:03 PM
Piper Sandler begins coverage of $STTK with an Overweight rating and $15 target, highlighting promise of SL-325 ahead of Phase 1 data. https://notreload.xyz/piper-sandler-starts-coverage-on-shattuck-labs-with-bullish-view/
0 · Reply
JFais
JFais Jan. 28 at 2:59 PM
$STTK (NP) $700MC (fully diluted), $550M EV (with warrants exercised) Running up into Q2 data for SL-325 (first DR3 blocking antibody in clinic) Big idea = they can achieve more potent & durable blockade vs competitors solely pursuing TL1A (Roche $ROIV $7B comp comes to mind)
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 22 at 12:48 PM
$STTK RSI: 65.22, MACD: 0.4316 Vol: 0.59, MA20: 4.06, MA50: 3.10 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockScanners
StockScanners Jan. 10 at 4:24 AM
$STTK reached 4.94
0 · Reply